Trial · NCT03505788

Acetazolamide in Decompensated Heart Failure With Volume OveRload (ADVOR)

NCT03505788, Phase 4, Completed, Ziekenhuis Oost-Limburg; results first posted 2024-10-28

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Acetazolamide in Decompensated Heart Failure With Volume OveRload (ADVOR). Trials, record NCT03505788. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03505788

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Acetazolamide in Decompensated Heart Failure With Volume OveRload (ADVOR)
NCT number: NCT03505788
Status: Completed
Phases: Phase 4
Enrollment: 519 participants, actual
Lead sponsor: Ziekenhuis Oost-Limburg
Conditions: Acute Decompensated Heart Failure, Volume Overload
Interventions: Acetazolamide, Placebo
First posted: 2018-04-23
Last updated: 2024-10-28
Results first posted: 2024-10-28
Limitations and caveats: 1. Nearly all patients were white~2. Patients had a history of chronic heart failure and had been receiving long-term outpatient treatment with at least 40 mg of furosemide equivalent.~3. Patients in the two trial groups received similar loop diuretics.~4. The congestion score focused on the presence of edema in the lower limb, pleural effusion, and ascites - reflective of mainly extracellular volume overload~5. The trial design excluded use of SGLT2 inhibitors

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Successful Decongestion	4 days	defined as the absence of signs of volume overload, within 3 days after randomization and with no indication for escalation of decongestive therapy.
Secondary	Mortality	3 months	All-cause mortality during the first 3 months after start of the study
Secondary	Hospital Readmission	3 months	If a patient is readmitted to the hospital within 3 months, this data will be collected
Secondary	Length of Index Hospital Admission	3 months	The time frame between hospital admission and discharge will be calculated
Secondary	EuroQoL Five Dimensions Questionnaire (EQ-5D)	at baseline, day 4 (or discharge), at 3 months	A questionnaire about the patients' quality of life will be performed at baseline, the morning of day 4, at any readmission, 3 months. The questionnaire is divided into 5 levels of severity with a score varying from 1 to 5. 1 indicates no problems and 5 indicates severe problems. The EQ-5D-5L health status, defined by the EQ-5D-5L descriptive system, are converted into a single index value (utility data). Values are anchored at 1 (full health) and 0 (a state as bad as being dead) as required by their use in economic evaluation. Values less than 0 represent health states regarded as worse than a state that is as bad as being dead.

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Successful Decongestion	4 days	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Mortality	3 months	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Hospital Readmission	3 months	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Length of Index Hospital Admission	3 months	days	GEOMETRIC_MEAN
SECONDARY	EuroQoL Five Dimensions Questionnaire (EQ-5D)	at baseline, day 4 (or discharge), at 3 months	score on a scale	MEAN

Source ClinicalTrials.gov

Results by group14

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Successful Decongestion	Placebo		79		Participants
Successful Decongestion	Acetazolamide		108		Participants
Mortality	Placebo		31		Participants
Mortality	Acetazolamide		39		Participants
Hospital Readmission	Placebo		45		Participants
Hospital Readmission	Acetazolamide		47		Participants
Length of Index Hospital Admission	Placebo		9.9	95% Confidence Interval 9.1 to 10.8	days
Length of Index Hospital Admission	Acetazolamide		8.8	95% Confidence Interval 8.0 to 9.5	days
EuroQoL Five Dimensions Questionnaire (EQ-5D)	Placebo	Baseline	0.571	Standard Deviation 0.027	score on a scale
EuroQoL Five Dimensions Questionnaire (EQ-5D)	Acetazolamide	Baseline	0.546	Standard Deviation 0.027	score on a scale

1 to 10 of 14Source ClinicalTrials.gov

See all 14 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	260
Overall Study	STARTED	Acetazolamide	259
Overall Study	COMPLETED	Placebo	257
Overall Study	COMPLETED	Acetazolamide	254
Overall Study	NOT COMPLETED	Placebo	3
Overall Study	NOT COMPLETED	Acetazolamide	5

Source ClinicalTrials.gov

Adverse events46

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Cardiac arrhythmia	Cardiac disorders	Placebo	30	259
other	Cardiac arrhythmia	Cardiac disorders	Acetazolamide	29	256
other	Decreased and nonspecific blood pressure disorders and shock	Cardiac disorders	Placebo	14	259
other	Decreased and nonspecific blood pressure disorders and shock	Cardiac disorders	Acetazolamide	20	256
other	Heart failure	Cardiac disorders	Placebo	83	259
other	Heart failure	Cardiac disorders	Acetazolamide	69	256
other	Hyperkaelemia	General disorders	Placebo	19	259
other	Hyperkaelemia	General disorders	Acetazolamide	14	256
other	Hypokaelemia	General disorders	Placebo	38	259
other	Hypokaelemia	General disorders	Acetazolamide	60	256

1 to 10 of 46Source ClinicalTrials.gov

See all 46 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Placebo	31	259
Total, all-cause mortality	Acetazolamide	39	256
Total, other adverse events	Placebo	184	259
Total, other adverse events	Acetazolamide	192	256
Total, serious adverse events	Placebo	124	259
Total, serious adverse events	Acetazolamide	123	256

Source ClinicalTrials.gov

Papers5

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
36027559	DERIVED	PubMed
36335479	DERIVED	PubMed
37197845	DERIVED	PubMed
37623428	DERIVED	PubMed
39171394	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons5

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Acetazolamide vs Placebo: Successful Decongestion	Trial comparisons
Acetazolamide vs Placebo: Mortality	Trial comparisons
Acetazolamide vs Placebo: deaths from any cause	Trial comparisons
Acetazolamide vs Placebo: Hospital Readmission	Trial comparisons
Acetazolamide vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03505788

GET https://conductscience.org/api/trials/v1/NCT03505788/events?page=2

API reference For AI assistants